HopeStage
Back to all studies
CompletedNCT03539887

Intranasal Ketamine for Suicidal Thoughts With Depression or Bipolarity

About this titleRead the official source — NCT03539887
Medication studyAges 21–60United States
The study in practice

Understand this study

Who was this study for?

Listed age limits: 21 years to 60 years.

Listed locations
HoustonSee all locations and recruitment
Study phase
Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.

Get this study by email

HopeStage may email me about this study.
Loading the security check...
Study clarity

Study information

Study start dateStarted: May 1, 2018
Recruitment status
Completed
Enrollment listed in the registry
33
Sponsor
The University of Texas Health Science Center, Houston
Sponsor type
University
Study type
Drug
Intervention type
Drug
Study phase
Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.
Locations
United States
Age range
From 21 Years to 60 Years
Official registry ID
NCT03539887
Official title
Show the full official title

A Randomized, Double-Blind, Placebo-Controlled Trial of the Rapid Antisuicidal Effects of Intranasal Ketamine in Comorbid Depression and Alcohol Abuse

Looking for a study you can join?

Explore recruiting studies

Recruitment & locations

Completed

Houston

Interested in joining this study?

HopeStage may email me about this study.
Loading the security check...
FAQ

Questions about this study

Who is behind this study?

The study sponsor is The University of Texas Health Science Center, Houston, a university.

Did this study involve medication?

Yes. The study involved medication, including Intranasal ketamine and Placebo.

Who was this study for?

Listed age limits: 21 years to 60 years.

Want to explore more studies?

Explore studies